

**ABSTRACT OF THE DISCLOSURE**

[00126] The invention relates to methods for determining a subject's susceptibility to cytotoxic drug therapy, by determining what polymorphic form of p53 the subject expresses. Also, a part of the invention are methods for identifying susceptible subjects, by assaying for mutated forms of p53. Therapeutic approaches based on this are also contemplated.